Labor and Delivery Complication

2

Review clinical trials related to Labor and Delivery Complication. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Azithromycin Prophylaxis for PRElabor CEsarean DElivery Trial

This is a phase-III multi-center double-blind randomized controlled trial of 8,000 individuals undergoing a scheduled or prelabor cesarean delivery who are randomized to either adjunctive azithromycin prophylaxis or to placebo. Both groups also will receive standard of care preoperative antibiotics (excluding azithromycin). The primary endpoint is a maternal infection composite defined as any one of the following up to 6 weeks postpartum: endometritis, wound infection, abscess, septic thrombosis, sepsis, pneumonia, pyelonephritis and breast infection.

Participants needed: 8,000
Trial details
Phase: Phase 3Biological sex: FemaleType: InterventionalSponsor: The George Washington University Biostatistics CenterUpdated: Apr 9, 2026Locations: 14
Eligibility criteria

≥ 23 weeks' gestation (ACOG dating criteria) [+2]

Allergy or contraindication to azithromycin or macrolide antibiotics, including... [+11]

Status: Recruiting

Maternal Oxygen Supplementation for Intrauterine Resuscitation

More than 80% of the 3 million women who labor and deliver each year in the United States undergo continuous electronic fetal monitoring (EFM) during labor in order to fetal hypoxia and prevent the transition to acidemia, expedited operative delivery, and/or neonatal morbidity. Category II EFM is the most commonly observed group of fetal heart rate features in labor. One common response to Category II EFM is maternal oxygen (O2) supplementation. The theoretic rationale for O2 administration is that it increases O2 transfer to a hypoxic fetus. There are conflicting national guidelines regarding O2 administration - the American College of Obstetricians and Gynecologists suggest O2 is ineffective, whereas the Association of Women's Health, Obstetric, and Neonatal Nurses recommend continued use given lack of definitive data on safety and efficacy. A recent national survey of nearly 600 Labor \& Delivery providers in February 2022 revealed that 49% still use O2 . Thus, there remains equipoise on the topic and high-quality data on the safety of intrapartum O2 is needed. None of the trials to date have studied the effect of intrapartum O2 on important clinical measures of neonatal or maternal morbidity. This safety data is imperative because the field of obstetrics must hold supplemental O2 to the same rigorous standards applied to any drug used in pregnancy. Without data on these definitive outcomes, it will be challenging to implement evidence-based recommendations for supplemental O2 use on Labor \& Delivery. The investigators will conduct a large, multicenter, randomized noninferiority trial of O2 supplementation versus room air in patients with Category II EFM in labor.

Participants needed: 2,124
Trial details
Biological sex: FemaleType: InterventionalSponsor: Washington University School of MedicineUpdated: Feb 27, 2026Locations: 1
Eligibility criteria

Singleton gestation [+4]

Preterm gestation [+5]